Mr Patrick Hilley
Research Fellow, Gastroenterology
Department of Medicine
27 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
Implementation of values-based healthcare in inflammatory bowel disease—a review
DOI: 10.1093/ecco-jcc/jjaf1732025
Journal article
Combination Advanced Therapies for Control of Ulcerative Colitis During Pregnancy
DOI: 10.14309/crj.00000000000019202025
Journal article
Editorial: Redefining Safety in Post-Liver Transplant IBD—Why Therapeutic Effectiveness Is the Ultimate Shield. Authors' Reply
DOI: 10.1111/apt.703412025
Journal article
Systemic Biologics Have Similar Safety to Vedolizumab in Inflammatory Bowel Disease Patients Following Liver Transplantation
DOI: 10.1111/apt.702832025
Conference Proceedings
P66 Systemic biologics have comparable safety to vedolizumab in inflammatory bowel disease patients following liver transplantation
DOI: 10.1136/gutjnl-2025-bsg.2022025
Journal article
How Does an Integrated Pharmacist Add Value in the Management of Inflammatory Bowel Disease in the Era of Values-Based Healthcare?
DOI: 10.1093/ibd/izae1962025
Journal article
P1012 Systemic biologic therapies are associated with comparable safety outcomes to vedolizumab for the management of Inflammatory Bowel Disease following liver transplantation
DOI: 10.1093/ecco-jcc/jjae190.1186
RECENT SCHOLARLY WORKS
2024
Journal article
Safety and Effectiveness of Janus Kinase Inhibitors in the Management of Inflammatory Bowel Disease Following Liver Transplantation
DOI: 10.1093/ecco-jcc/jjae0392024
Journal article
Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial
DOI: 10.1136/bmjopen-2023-0817872024
Conference Proceedings
Transitioning patients from intravenous to subcutaneous infliximab and vedolizumab for inflammatory bowel disease: what is the opportunity cost of improving access to healthcare?
DOI: 10.1111/imj.16311